Roth Capital Has Negative Outlook for ALUR Q1 Earnings

Allurion Technologies Inc. (NYSE:ALUR) – Equities researchers at Roth Capital decreased their Q1 2025 earnings estimates for Allurion Technologies in a report released on Wednesday, March 26th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of ($1.18) for the quarter, down from their previous forecast of ($0.92). The consensus estimate for Allurion Technologies’ current full-year earnings is ($9.96) per share. Roth Capital also issued estimates for Allurion Technologies’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.57) EPS and FY2026 earnings at ($0.53) EPS.

Allurion Technologies (NYSE:ALUR) last announced its earnings results on Wednesday, March 26th. The company reported ($7.00) earnings per share for the quarter, missing the consensus estimate of ($5.00) by ($2.00). The firm had revenue of $5.59 million for the quarter, compared to analyst estimates of $5.60 million.

A number of other research analysts also recently commented on ALUR. Roth Mkm reissued a “buy” rating and issued a $16.00 price target on shares of Allurion Technologies in a report on Friday, March 21st. Chardan Capital reiterated a “neutral” rating and set a $2.50 target price on shares of Allurion Technologies in a research note on Thursday, March 27th.

Allurion Technologies Price Performance

NYSE:ALUR opened at $3.33 on Monday. The firm has a 50-day moving average of $4.03 and a two-hundred day moving average of $9.49. The stock has a market cap of $15.94 million, a P/E ratio of -0.28 and a beta of -0.59. Allurion Technologies has a 1-year low of $2.15 and a 1-year high of $98.75.

Hedge Funds Weigh In On Allurion Technologies

An institutional investor recently raised its position in Allurion Technologies stock. Geode Capital Management LLC increased its holdings in Allurion Technologies Inc. (NYSE:ALUR) by 40.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 516,330 shares of the company’s stock after buying an additional 149,484 shares during the period. Geode Capital Management LLC owned about 0.80% of Allurion Technologies worth $317,000 as of its most recent filing with the SEC. 21.39% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Allurion Technologies

In other news, CEO Shantanu Gaur purchased 8,000 shares of the stock in a transaction dated Friday, March 28th. The stock was acquired at an average cost of $3.35 per share, for a total transaction of $26,800.00. Following the acquisition, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $26,800. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 22.40% of the company’s stock.

About Allurion Technologies

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.